Antifungal therapy – Page 14

Caspofungin therapy in prosthetic valve endocarditis and candidemia due to itraconazole-resistant Candida glabrata (Nakaseomyces glabratus): A case report

mycolabadmin

A 13-year-old boy developed a serious fungal infection of his heart valve after surgery. The infection was caused by a resistant yeast that didn’t respond to initial antifungal treatment. Doctors used molecular testing to identify the exact fungal species and tested how it responded to different medications. After switching to a different antifungal drug called caspofungin, the patient recovered completely and remained healthy.

A Rare Case of Alternaria citri Keratitis Successfully Treated with Voriconazole

mycolabadmin

A 71-year-old woodworker developed a serious eye infection caused by a rare fungus called Alternaria citri that damaged his cornea. Doctors identified the fungus using genetic testing and treated it with the antifungal drug voriconazole combined with surgery. After one year, his vision improved and the infection did not return, marking the first documented case of this particular fungal infection in humans.

Disseminated subcutaneous sporotrichosis in an immunocompetent patient: A case report and a systematic literature review

mycolabadmin

A 74-year-old man developed painful red masses on his arm and hand after being stuck by a tree branch. Tests identified the infection was caused by a fungus called Sporothrix schenckii. Despite having a normal immune system, the infection had spread across his arm in an unusual pattern. Treatment with an antifungal medication called itraconazole completely healed the lesions within four months without any scarring.

Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Aspergillus fumigatus growth

mycolabadmin

This study examines how Trikafta, a new cystic fibrosis medication, affects a common fungal lung infection (Aspergillus fumigatus). The researchers found that Trikafta doesn’t directly kill the fungus but does make it more susceptible to antifungal drugs and improves lung clearance. Surprisingly, at high concentrations, the medication actually reduced the immune response against the fungus in immune cells, suggesting the need for careful monitoring of patients on this therapy.

Brazilian task force for the management of mucormycosis

mycolabadmin

Mucormycosis is a rare but deadly fungal infection that has been increasingly reported in Brazil, especially during the COVID-19 pandemic. This Brazilian medical task force developed practical guidelines for diagnosing and treating this serious infection, which primarily affects people with uncontrolled diabetes or weakened immune systems. The key to survival is early diagnosis combined with aggressive surgery and specific antifungal medications, along with controlling blood sugar and immune system suppression.

Co-Infection of Pulmonary Aspergillosis and Cryptococcal Meningitis in an HIV-Positive Patient: A Case Report

mycolabadmin

This case describes a man with undiagnosed HIV who developed two serious fungal infections at the same time: a lung infection caused by Aspergillus fungus and a brain infection caused by Cryptococcus fungus. His extremely low immune system (CD4 count of 41) made him vulnerable to multiple opportunistic infections. Despite treatment with antifungal medications, his condition worsened and he passed away, highlighting the dangers of late HIV diagnosis.

A Case of Superficial Mycoses in a Patient with Systemic Lupus Erythematosus

mycolabadmin

A 52-year-old woman with lupus developed severe fungal skin infections that were initially mistaken for worsening lupus symptoms. Her condition improved after 6 months of treatment with two antifungal medications (terbinafine and itraconazole). This case reminds doctors that patients taking immunosuppressive medications for lupus are at high risk for fungal infections, which can be misdiagnosed as lupus flares.

Pulmonary Aspergilloma in a Non-adherent Systemic Lupus Erythematosus Patient Receiving Long-Term Immunosuppression: A Report of a Rare Case

mycolabadmin

A patient with systemic lupus erythematosus (SLE), a chronic autoimmune disease treated with long-term immune-suppressing medications, developed a serious fungal lung infection called pulmonary aspergilloma. Despite the complexity of managing multiple conditions and extensive bilateral lung involvement, the patient was successfully treated with prolonged voriconazole antifungal therapy rather than surgery, emphasizing the importance of early recognition and tailored treatment in immunocompromised patients.

Fungal Sinusitis Spreading to the Sellar Region Mimicking a Pituitary Tumor: Case Report and Literature Review

mycolabadmin

A 56-year-old woman was found to have a large mass in her sinus cavity that had eroded bone and spread to the area around her pituitary gland, mimicking a pituitary tumor. Through surgery and pathological examination, doctors discovered it was actually a fungal infection (fungus ball) rather than a tumor. This case report reviews 67 similar patients from medical literature to help doctors better recognize and treat these rare fungal infections that can threaten vision and endocrine function.

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

mycolabadmin

This study reviewed clinical trials comparing a newer antifungal drug called isavuconazole with other commonly used antifungal medications for treating serious fungal infections, particularly in patients with weakened immune systems. The research found that isavuconazole works just as well as other antifungal drugs but may have fewer side effects, especially liver problems. When compared directly with voriconazole, isavuconazole showed fewer drug-related side effects overall, making it a good alternative option for patients who cannot tolerate other antifungal treatments.

Research Topic: Antifungal therapy